Sign inCreate account

Report workspace tools

NCT01027598COMPLETEDanonymous

A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Sponsor

Source record

SCRI Development Innovations, LLC

Phase

Source record

Phase II

Modality

AI-normalized

small molecule

Target

AI-normalized

Non-Small Cell Lung Cancer (NSCLC)

Indication / condition

AI-normalized

Non Small Cell Lung Cancer

Intervention

Source record

Pazopanib, Erlotinib

Source & freshness

Source record

NCT ID

NCT01027598

Original source

ClinicalTrials.gov

Source last updated

Jan 29, 2016

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01027598

Title

A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Sponsor

SCRI Development Innovations, LLC

Status

COMPLETED

Phase

Phase II

Condition raw

Non Small Cell Lung Cancer

Condition normalized

Non Small Cell Lung Cancer

Modality raw

Non Small Cell Lung Cancer

Modality normalized

small molecule

Target raw

Non-Small Cell Lung Cancer (NSCLC)

Target normalized

Non-Small Cell Lung Cancer (NSCLC)

Interventions

Pazopanib, Erlotinib

Public preview

Source record

This trial evaluated the efficacy of combining erlotinib with pazopanib versus erlotinib alone in patients with previously treated advanced NSCLC. The study aimed to improve progression-free survival (PFS) by targeting both EGFR and VEGFR pathways.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01027598

Status

COMPLETED

Phase

Phase II

Sponsor

SCRI Development Innovations, LLC

Executive brief

Investment-Ready Snapshot

This trial evaluated the efficacy of combining erlotinib with pazopanib versus erlotinib alone in patients with previously treated advanced NSCLC. The study aimed to improve progression-free survival (PFS) by targeting both EGFR and VEGFR pathways.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 29, 2016
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01027598

Indication

Non Small Cell Lung Cancer

Modality

small molecule

Target

Non-Small Cell Lung Cancer (NSCLC)

Intervention

Pazopanib, Erlotinib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.